Electrochemiluminescent detection of donepezil

The move towards personalized precision medicine, requires monitoring of drug therapies as well as progression makers. Indeed, the monitoring of drug therapies is essential for the continuing evolution of precision medicine in conjunction with drug development and targeted treatment strategies. This study presents the feasibility of electrochemiluminescence (ECL) for the detection of donepezil hydrochloride (DZ) as a proof-of-concept for point-of-care applications within human pooled serum and artificial urine. ECL has the potential to be an easily understood point-of-care sensor increasing its potential for translation as the intensity of the emitted light is proportional to the target analyte concentration. This proof-of-concept demonstrated its ability to detect DZ over the clinically relevant concentration range of 0.5 to 1000 μM, and was effective at detecting 0.5, 1, 1.5 and 7.5 μM spiked into human pooled serum and artificial urine. While more development is still needed, this highlights the applicability of electrochemical sensors, including ECL based sensors, for point-of-care devices with the reduction of sample preparations improving its feasibility for clinical and point-of-care applications. • First ECL monitoring of donepezil hydrochloride • Detection down to clinically relevant concentrations within artificial urine and human pooled serum • Detection achieved in the presence of commonly prescribed drugs which are electrochemically active offering the potential for dual detection within therapeutically relevant range